Two drug manufacturers are sending 340B covered entities refunds for overcharges totaling $100 or more, according to public filings posted [...] …
Category: Providers
Eligible covered entities in Hawaii may enroll in the 340B program immediately rather than having to wait for the next [...] …
The hiring of lobbyists in the congressional legislative fight over 340B was dominated by pharmaceutical firms and provider-manufacturer alliances in [...] …
The 340B drug pricing program does not improve inpatient care quality for underserved patients, a recent government-funded analysis concluded. A [...] …
GlaxoSmithKline is sending 340B covered entities refunds for overcharges totaling $100 or more for purchases of two dosage forms of [...] …
While two drug manufacturers have recently relaxed or suspended their 340B contract pharmacy restrictions as a result of state laws [...] …
The lead plaintiff in the legal battle that resulted in Medicare proposing an unusual lump sum payback for hospitals’ lost [...] …
Congress should let for-profit hospitals into the 340B drug pricing program as “a long overdue evolutionary step” that will advance [...] …
Changes in the ways Medicare calculates hospitals’ shares of low-income patients that were finalized in a recent payment rule will [...] …
Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...] …